Citations

1. DeLong MR, Juncos JL (2005). Parkinson's disease and other movement disorders. In DL Kasper et al., eds., Harrison's Principles of Internal Medicine, 16th ed., pp. 2406–2418. New York: McGraw-Hill.

2. Clarke CE, Guttman M (2002). Dopamine agonist monotherapy in Parkinson's disease. Lancet, 360(9347): 1767–1769.

3. Clarke C, Moore AP (2005). Parkinson's disease. Clinical Evidence (14): 1652–1668.

4. Korczyn AD, Nussbaum M (2002). Emerging therapies in the pharmacological treatment of Parkinson's disease. Drugs, 62(5): 775–786.

5. Stacy M, Factor S (2004). Rapid treatment of "off" episodes: Will this change Parkinson's disease therapy? Neurology, 62(6, Suppl 4): S1–S2.

6. Miyasaki JM, et al. (2002). Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review. Neurology, 58(1): 11–17.

7. Hobson DE, et al. (2002). Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease. JAMA, 287(4): 455–463.

8. Samii A, et al. (2004). Parkinson's disease. Lancet, 363(9423): 1783–1793.

9. Shults CW, et al. (2002). Effects of coenzyme Q10 in early Parkinson disease. Archives of Neurology, 59(10): 1541–1550.

10. Storch A, et al. (2007). Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson's disease. Archives of Neurology, 64(7): 938–944.

Other Works Consulted

• Deuschl G, et al. (2006). A randomized trial of deep-brain stimulation for Parkinson's disease. New England Journal of Medicine, 355(9): 896–908.

• Juncos JL, DeLong MR (2005). Parkinson disease and other movement disorders. In DC Dale, DD Federman, eds., ACP Medicine, section 11, chap. 15. New York: WebMD.

• Miyasaki JM, et al. (2006). Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66(7): 996–1002.

• Pahwa R, et al. (2006). Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66(7): 983–985.

• Siderowf A, Stern M (2003). Update on Parkinson disease. Annals of Internal Medicine, 138(8): 651–658.

• Suchowersky O, et al. (2006). Practice parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66(7): 968–975.

• Suchowersky O, et al. (2006). Practice parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66(7): 976–982.